

June 17, 2024

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: [ir@ppmx.com](mailto:ir@ppmx.com)

### **Announcement of Acceptance of Presentation of PPMX-T003 Phase I Interim Report at the 14th JSH International Symposium 2024**

Perseus Proteomics Inc. is pleased to announce that the interim report presentation of phase I clinical trial of PPMX-T003, its anti-transferrin receptor 1 antibody, among polycythemia vera ("PV") patients has been accepted at the 14th JSH International Symposium 2024 in Hakodate.

Date: July 13 – 14, 2024

Title: PHASE I STUDY OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY (PPMX-T003) IN PATIENTS WITH POLYCYTHEMIA VERA (INTERIM REPORT)

Author: Tomoki Ito/First Department of Internal Medicine, Kansai Medical University

Teruhito Takakuwa, Masayuki Hino, Hirohisa Nakamae/Department of Hematology, Osaka Metropolitan University

Kazunori Murai/Department of Hematology, Iwate Prefectural Central Hospital

Yoko Kubuki, Kazuya Shimoda/Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki

Tadashi Matsuura/Perseus Proteomics Inc.

Presenter: Tadashi Matsuura

While the observation period of 5 subjects have finished, the interim report on safety and efficacy based on the data confirmed with clinical records will be presented before final reporting.

END